Commercial Operating System

Transition Industries LLC and IFC announce agreement to develop net-zero world-scale methanol project in Sinaloa, Mexico

Retrieved on: 
Thursday, December 7, 2023
Other Transport, Green Technology, Manufacturing, Maritime, Environment, Transport, Sustainability, Finance, Environmental Issues, Professional Services, Logistics, Supply Chain Management, Other Energy, Utilities, Oil, Gas, Alternative Energy, Energy, Other Manufacturing, Chemicals, Plastics, Carbon, Coal, Climate change, Employment, World Bank Group, Natural Resources, Developed country, Commercial Operating System, Investment, International Finance Corporation, Methanol, JPDA, Deep Decarbonization Pathways Project, Ecosystem, Natural gas, Low Transit Industries, Partnership, Water, Government agency, COP, ESG, Drug

Transition Industries LLC announced at COP 28 that it has signed a Joint Project Development Agreement (JPDA) with the International Finance Corporation (IFC), a member of the World Bank Group, to jointly develop its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico.

Key Points: 
  • Transition Industries LLC announced at COP 28 that it has signed a Joint Project Development Agreement (JPDA) with the International Finance Corporation (IFC), a member of the World Bank Group, to jointly develop its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico.
  • Under the terms of the JPDA, the IFC will share a portion of the project development costs, provide substantial expertise to ensure compliance with the IFC Performance Environmental & Social Standards, and leverage its expertise to support the project financing.
  • Rommel Gallo, the CEO of Transition Industries, commented: “We are pleased to announce our JPDA with the IFC and proud to partner on this groundbreaking project.
  • The project is expected to generate on average 3,500 jobs during construction and up to 450 jobs during operations.

Ribbon Biolabs Appoints Jodi Barrientos Chief Executive Officer; Founder Harold De Vladar Named an Advisor and Board Member

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Barrientos, DNA, Pathology, Commercial, Commercial Operating System, Roche, Genomics, Agilent Technologies, New England Biolabs, Advertising, Molecular biology, Growth, Microbiology, Purdue University, Qiagen, Management

Ribbon Biolabs GmbH, the DNA synthesis company, announced today that its Board of Directors had appointed Jodi Barrientos as interim Chief Executive Officer.

Key Points: 
  • Ribbon Biolabs GmbH, the DNA synthesis company, announced today that its Board of Directors had appointed Jodi Barrientos as interim Chief Executive Officer.
  • Ms. Barrientos, who joined the company this year as Chief Business Officer, brings substantial market experience to Ribbon Biolabs, as it moves forward with its commercialization plan.
  • Founder and former CEO Harold de Vladar, Ph.D., will serve as a senior advisor to the company and member of the Board.
  • Said Roopom Banerjee, Managing Partner of Whiteleaf Advisors, and Executive Chairman of the Board at Ribbon Biolabs, “We are so excited that Ribbon Biolabs has reached an inflection point under Harold’s leadership where commercial leadership is critical to the continued growth of the company.

Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Oral Solution

Retrieved on: 
Monday, December 4, 2023
Biotechnology, FDA, Managed Care, Health, General Health, Women, Seniors, Pharmaceutical, Research, Consumer, Science, Breakfast, Heat intolerance, Absorption, Food, Hypothyroidism, Eating, Commercial Operating System, Irritability, Headache, Risk, Tremor, Arrhythmia, IBSA, Rash, Cardiovascular disease, Insurance, Patient, Diabetes, Myocardial infarction, Periodic breathing, Appetite, Atrial fibrillation, Muscle weakness, Enzyme inhibitor, Adrenal insufficiency, Diarrhea, Menstruation, University, Water, Insomnia, PPI, Glycerol, Common, Spasm, Nervous, Hyperthyroidism, Weight loss, Pharmacy, Pharmaceutical industry, Dietary supplement, Levothyroxine

The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.
  • The first regards the use of Tirosint-SOL in the presence of proton pump inhibitor (PPI) therapy.
  • Both label changes help to differentiate Tirosint-SOL from other levothyroxine therapies.
  • Similarly, current labeling for all levothyroxine sodium therapies instructs patients to self-administer the drug once daily, on an empty stomach, one-half to one hour before breakfast.

 Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points: 
  • Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
  • Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
  • I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

Innovative Digital CX Partnership Delivers AI-Powered Results for Global Enterprises

Retrieved on: 
Friday, November 17, 2023
Marketing, Communications, Technology, Software, Other Communications, Artificial Intelligence, Cloud, Carbon, Self-service, GM, Organization, Commercial Operating System, Beauty, Fintech, Research, Public sector, Map, CX, Automation, Digital, Success, CCAA, Partnership, Biophysical environment, AI, Human, SVP, ESG, Sales, Social, Genesys, Theretra alorica

To help enterprise clients worldwide offer seamless omnichannel experiences, Alorica has implemented Genesys Cloud CX® for its extensive AI and digital capabilities, track-record of innovation and proven resiliency, security and scalability.

Key Points: 
  • To help enterprise clients worldwide offer seamless omnichannel experiences, Alorica has implemented Genesys Cloud CX® for its extensive AI and digital capabilities, track-record of innovation and proven resiliency, security and scalability.
  • Coupled with Alorica’s managed services, scalable workforce, curriculum-as-a-service and award-winning analytics , Genesys bolsters Alorica IQ --the CX provider’s digital foundry--to deliver outcome-based technology solutions that map and solve customer pain points.
  • Currently, Genesys Cloud CX is supporting thousands of Alorica employees in delivering exceptional results for its first wave of global clients spanning diverse industries including fintech, retail, gaming, telecommunication, public sector and more.
  • Through Alorica’s partnership with Genesys, the digital CX provider can provide its clients the manpower, technology and vision to support their needs both now and in the future.

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Uveal melanoma, MDSC, Webcast, Sale, Interest, Liver disease, Pressure, Policy, ICI, Cancer, Commercial Operating System, Liver, Investment, Patient, PFS, Tumor microenvironment, Marketing, FACS, Neoplasm, TME, MD, SITC, Growth, Immunotherapy, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • “Today marks an important milestone for TriSalus as we host our first quarterly earnings call as a public company.
  • The seven percent improvement in the third quarter of 2023 is due to increased factory volumes and improved operations efficiency.
  • Operating losses are $18.5 million and $40.0 million, respectively, for the third quarter and nine months ended September 30, 2023.

Ascensia Diabetes Care takes part in MedTech Europe's 'Connecting the Dots' Film Series, with a film on Eversense® CGM

Retrieved on: 
Tuesday, December 5, 2023
Safety, Practitioner, Dots, Commercial Operating System, Physician, BBC Studios, Collection, CGM, Patient, Blood glucose monitoring, TSE, BBC, Diabetes, BGM, Medical device, MedTech Europe

Parsippany, N.J.  , Dec. 5, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces its participation in a new film series featuring the story of patient advocate and Eversense® user Troy Ita. Presented by MedTech Europe and including a film produced for the organization by BBC StoryWorks Commercial Productions, the branded content studio of BBC Studios, the 'Connecting the Dots' series brings into focus the evolution of medical technologies, celebrating both cutting-edge innovations and enduring healthcare solutions that empower people. The series is available on www.medtechconnectingthedots.com.

Key Points: 
  • Parsippany, N.J. , Dec. 5, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces its participation in a new film series featuring the story of patient advocate and Eversense® user Troy Ita.
  • In particular, the film highlights the transformation that Eversense, the only long-term CGM system, can deliver to people with diabetes, through the lens of Troy and his endocrinologist Dr. Rakesh Patel.
  • In the film, Troy said, "I'm constantly on the road driving for my job, so managing my diabetes has become a juggling act.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Irrigation Show 2023: Calsense introduces AI-powered Irrigation Assistant Cal as part of all-new Calsense Connect user experience

Retrieved on: 
Wednesday, November 29, 2023
Court of general sessions, SAN, Commercial Operating System, Synthetic media, Privacy, Weather, Element, Artificial intelligence, Machine learning, Booth, Irrigation Association, Water, Irrigation, AI, Knowledge, LLM, Video game, Canal, Agriculture, Cal

SAN ANTONIO, Nov. 29, 2023 /PRNewswire/ -- Calsense smart irrigation users will soon be able to get immediate answers to their pressing irrigation questions at any hour of the day or night thanks to 'Cal', the company's groundbreaking new AI-based Irrigation Assistant.

Key Points: 
  • With an intuitive question and response user interface, Cal is integrated into the new Calsense Connect™ unified user platform, available on all devices.
  • The user interface provided by Calsense Connect focuses on ease of use, offering real-time management and monitoring of all connected smart irrigation controllers.
  • Cal and Calsense Connect were unveiled today by smart irrigation pioneer Calsense at the ongoing Irrigation Show and Education Week 2023 in San Antonio, Texas.
  • "Our new Irrigation Assistant Cal is an example of Calsense's commitment to technology leadership in the smart irrigation industry, and our emphasis on the enhanced user experience," said Calsense Chief Product & Technology Officer Larry Heminger.

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

Retrieved on: 
Friday, November 17, 2023
ID, Corporation, Business development, Chemistry, NVAX, AstraZeneca, Senior, Commercial Operating System, Novavax, Boston Scientific, Suffolk University Law School, Hologic, Vaccine, Vancouver Island University, Rationalization, MedImmune, COVID-19, Long Island University, Business administration, Mallinckrodt, Dell, R, CMC, Infection, Syracuse University, Business, Master of Business Administration, Management, Science, New York University

GAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.

Key Points: 
  • GAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.
  • In this role, Mr. Trizzino will lead the commercial; chemistry, manufacturing and controls or CMC; and regulatory functions.
  • He will continue to serve on the Company's executive leadership team.
  • Mr. Casey will also serve on the Company's executive leadership team.

Florida Department of Children and Families Chooses Juno EHR from Juno Health

Retrieved on: 
Thursday, November 16, 2023
Cloud, FSH, EHR, Safety, Florida Department, Patient safety, Software, Commercial Operating System, ONC, DCF, Collection, Bed, Mental health, DSS, Software as a service, 21st Century Cures Act, Environment, Florida State Hospital, Nursing, Management, Service

JUNO BEACH, Fla., Nov. 16, 2023 /PRNewswire-PRWeb/ -- Juno Health, the commercial division of DSS, Inc., has announced that the Florida Department of Children and Families (DCF) has chosen Juno EHR as its electronic health record (EHR) for Florida State Hospital (FSH) in Chattahoochee, FL. DCF's stated vision for this implementation is to improve the delivery of care, improve collection and availability of clinical information, increase patient safety, and improve patient outcomes.

Key Points: 
  • JUNO BEACH, Fla., Nov. 16, 2023 /PRNewswire-PRWeb/ -- Juno Health , the commercial division of DSS, Inc., has announced that the Florida Department of Children and Families ( DCF ) has chosen Juno EHR as its electronic health record (EHR) for Florida State Hospital (FSH) in Chattahoochee, FL.
  • "We are excited that the DCF has chosen Juno EHR to advance its behavioral health capabilities through the use of a highly flexible and configurable EHR solution," said J. Michael Fehr, Vice President, Commercial Operations at Juno Health.
  • By implementing Juno EHR for Behavioral Health , Florida DCF is leveraging an EHR that is a browser based, cloud native solution that can support their mission now and in the future.
  • "We are excited that the DCF has chosen Juno EHR to advance its behavioral health capabilities through the use of a highly flexible and configurable EHR solution," said J. Michael Fehr, Vice President, Commercial Operations at Juno Health.